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Abstract
Background: Group B Streptococci (GBS) are the most common neonatal pathogens and infect
immunocompromised and elderly individuals. The species has 10 different serotypes. Serotypes have been
studied in the south-west area of Sweden in 1988–1997 and 1998–2001. The aim of this study was to study
serotypes in the same area from 2004 to 2009.
Methods: Invasive GBS isolates were collected prospectively from 2004 to 2009 in two counties in western Sweden
with a population of 1.8 million, and were serotyped by latex agglutination. Clinical data were obtained from hospital
records. During the study period 410 invasive GBS isolates from 398 patients were collected (multiple episodes
≥1 month apart). Clinical data were not available for two patients who are excluded. Four isolates were from stillborn
neonates, 88 were from live born neonates and infants, and 318 from adults.
Results: Serotype III was the most common serotype (48 %) in neonates and infants followed by serotypes Ia (18 %)
and V (16 %). In adults serotype V (39 %) dominated followed by serotypes III (20 %) and Ib (14 %). There was a
significant increase of serotype V in comparison with the first study (1988–1997) but there were no significant changes
in the serotype distribution between the present study and the second study (1998–2001). There were a few cases of
serotype VI-IX, both in children and adults, not seen in the previous studies. Serotype V was more common among
patients with arthritis than with any other manifestation.
Conclusions: Changes in GBS serotypes occur over time in the same region, which must be considered when GBS
vaccines are formulated.
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Background
Group B Streptococci (GBS) remain a leading cause of
invasive neonatal infections and an important cause of
infections in pregnant women, immune compromised
adults and the elderly [1–3]. GBS possess ten distinct
capsular polysaccharide (CPS) types: Ia, Ib and II-IX [4].
The principal disease-associated serotypes are currently
Ia, Ib, II, III and V [2, 5–7] according to studies from
North America and Norway.
Most centers in Sweden have been using a risk-based
prophylaxis strategy which identifies candidates for intra
partum antimicrobial prophylaxis (IAP) according to the
presence of any of the following risk factors: a previous
GBS-infected baby, positive for GBS in urine, delivering at
<37 weeks’ gestation, having an intra-partum temperature
≥38.0°, or rupture of membranes for ≥18 h. There is no
plan to begin with universal prenatal GBS screening
followed by IAP of all GBS carriers as is recommended by
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the US guidelines from 2002 [8, 9]. Both strategies have
dramatically reduced the incidence and mortality
among early onset (EO, <7 days after birth) GBS infec-
tions, but they have not reduced the incidence of late
onset (LO, 7–27 days after birth) or very late onset (VLO,
28 days–4 months after birth) disease [1, 10–13].
There are no efficacy studies of GBS vaccines, but
most likely protection would be achieved by anticapsular
serum antibodies as it is for other bacteria with polysac-
charide capsules. The first vaccines against GBS con-
sisted of pure polysaccharides and had disappointingly
low immunogenicity. Polysaccharide-protein conjugates
are more immunogenic and have been given in phase 1
to 2 clinical trials (including pregnant women with 1 to
5 serotypes. Proteins used have been tetanus toxoid or
genetically inactivated diphtheria toxoid [14]. To make
the best possible GBS vaccines they must be directed
against the polysaccharides of the most common GBS
serotypes.
It is important to follow the distribution of serotypes
since it may differ over time and between populations [3].
The main aim of this study was to survey the current
serotype distribution of invasive GBS infections in a
Swedish population and to compare it with previous
studies in the same area to detect any changes over time.
Methods
Invasive GBS isolates were collected prospectively be-
tween 2004 and 2009 from the six bacteriological labora-
tories, which served all 13 hospitals, in the counties of
Västra Götaland and Halland in western Sweden. The
mean population of the surveillance area was 1,828,140
which corresponds 20 % of the total population in Sweden
(9,128,308 inhabitants). The total number of live births
was 127,882 during the study period. (Central Bureau of
Statistics, Stockholm, Sweden (http://www.scb.se). The
two regions studied include the city of Gothenburg with
suburbs, (urban area population about 850,000, cities with
populations up to 100,000 inhabitants, small villages and
rural areas. There are no major socioeconomic differences
within the area studied nor between the area studied and
the rest of Sweden.
An invasive GBS case was defined as isolation of the or-
ganism from a normally sterile site (blood, cerebrospinal
fluid and synovial fluid) in a surveillance area resident. No
isolates came from pleural, pericardial or peritoneal fluid.
The total number of invasive GBS isolates during the
time period was 515. Thus of all isolates 410/515 (80 %)
were serotyped. The strains which were not serotyped
were evenly distributed during the time period and the
participating laboratories. Age, date of culture, possible
risk factors, and complications, were obtained from med-
ical records and an evaluation was made to see if death
was attributed to the GBS infection. One neonate had
protected identity, so its records could not be studied. The
records of one adult patient could not be found. These
two patients are excluded from all parts of the study.
Isolates were identified as GBS by colony morphology,
microscopy following Gram’s stain of smears, and co-
agglutination with group-specific reagents (Streptex;
Murex Biotech, Dartford, UK). The isolates were stored in
a broth at −70 °C until serotyping was performed using
the latex agglutination test with type-specific antisera for
serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII and IX (Statens
Serum Institut, Copenhagen, Denmark), as previously
described [15].
Only one isolate from each infectious episode was
included in the study and it was considered the same
episode if it was less than 30 days between the isolates.
GBS was isolated from 410 infectious episodes in 398
patients, 11 patients had more than one episode. Each
infectious episode is reported as a separate patient.
Statistics
Fisher’s exact test (two-tailed) was used for compari-
sons of proportions (http://graphpad.com/quickcalcs/
contingency1.cfm). A p value <0.05 was considered
significant.
Ethical approval
The study was approved by the Ethics Committees of
Gothenburg University and Lund University (registration
numbers Ö524-03, LU674-02). The committees did not
require individual consent, because the clinical data were
obtained in retrospect, when many patients and/or rela-
tives could not be found.
Results
Neonates and infants
A total of 91 invasive GBS isolates from 91 neonates and
infants aged 0–209 days were serotyped, 47 boys and 44
girls. Four were intra uterine fetal deaths (IUFD). Sepsis
without a known focus was the most common clinical
manifestation among live born neonates and infants with
63 cases (72 %). Meningitis was seen in 12 patients (14 %).
Other manifestations were pneumonia (eight patients), skin
infection (two patients), urosepsis (one patient) and septic
arthritis (one patient). Altogether 33 (38 %) live-born pa-
tients were preterm, i.e. gestational age <37 weeks, 20 had
EO disease, two had LO disease and 11 had VLO disease.
Serotype III was the most prevalent serotype (48 %) in
neonates and infants followed by serotype Ia (18 %) and
serotype V (16 %). The serotype distribution compared
to clinical manifestations is shown in Fig.1. Serotype III
was more common (p = 0.03) in patients with sepsis with
no known focus (IUFD not included) than the other se-
rotypes. There were no other significant differences re-
lated to clinical manifestations and serotypes.
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A total of seven children died because of invasive GBS
infection; all had sepsis, three were born full term and
four were born prematurely. A total of five were EO, one
VLO and one was 122 days old. They had a variety of se-
rotypes with no one dominating.
Adults
There were 317 adults (median age 73 years (23–103
years) 170 males and 147 females). Underlying medical
conditions were documented in 259 (81 %), the most
common being cardiovascular disease (n = 114), diabetes
(n = 80) and malignant disease (n = 62).
Serotype V was the most prevalent serotype (39 %)
followed by serotypes III and Ib (20 and 14 %, respectively)
(Table 1). There were a few significant relations between
serotype and clinical manifestation. Serotypes V and III
were more common among patients with septic arthritis
than with any other manifestation (p = 0.008 and p = 0.03
respectively). Otherwise there was no difference in the
serotype distribution related to clinical manifestations
(Table 2).
During the study period 38 patients (12 %) died during
or within 30 days after the infection, 20 (53 %) had sepsis
with unknown focus. Other manifestations were erysipelas
(five), pneumonia (four), endocarditis (three), urosepsis
(three), meningitis (one), septic arthritis (one), and med-
iastinitis (one). Only five of the patients who died did not
have a known underlying medical condition, three were
older than 72 years, one woman at age 53 died in multi
organ failure 2 days after diagnosis of sepsis, one woman
died at the age of 24 because of pneumonia, she had given
birth 17 days prior to death. The serotypes isolated from
the patients who died were V (12), III (ten), Ia (five), II
(five), Ib (three), IV (two) and IX (one). No difference in
serotype distribution could be seen among the fatal infec-
tions and in patients who survived.
Recurrent or reinfections
A total of 11 patients, all adults with a preexisting under-
lying condition, had more than one episode at intervals
from 2 to 23 months. The second infection was caused by
a different serotype in six patients and by the same sero-
type in 5 patients (Table 3). The clinical manifestations
varied but were the same in both (or all three) second in-
fections in 8 patients.
Differences between children and adults
The major difference between children (neonates and in-
fants) and adults was that serotype III was much more
common among children (p < 0.0001) and serotype V
among adults (p < 0.0001). Serotype Ib was also more
common among adults than children (p = 0.029).
Fig. 1 Serotype distribution among live-born neonates and infants (n = 87) with different manifestations. *Other: Pneumonia (8), Erysipelas (2),
Urosepsis (1), Septic Arthritis (1)
Table 1 Serotype distribution among invasive group B
streptococci





Serotype No. (%) No. (%) No. (%) No. (%) No. %
Ia 1 (25) 12 (20) 4 (13) 34 (11) 51 (12)
Ib 5 (9) 0 (0) 45 (14) 50 (12)
II 3 (5) 2 (7) 29 (9) 34 (8)
III 3 (75) 24 (41) 20 (67) 62 (20) 109 (27)
IV 1 (2) 1 (3) 14 (4) 16 (4)
V 11 (19) 1 (3) 124 (39) 136 (33)
VII 1 (2) 0 (0) 0 (0) 1 (<1)
VIII 0 (0) 1 (3) 3 (1) 4 (1)
IX 1 (2) 1 (3) 7 (2) 9 (2)
Total 4 58 30 318 410
aIntra Uterine Fetal Death
Gudjónsdóttir et al. BMC Infectious Diseases  (2015) 15:507 Page 3 of 7
Comparison of the present study with two earlier studies
from the same area
The main aim of this study was to survey the serotype
distribution of invasive GBS infections and to compare it
with previous studies in the same area to detect any
changes over time.
Table 4 compares the serotype distribution with re-
sults from previous studies in the same region [16, 17].
There was a significant increase of serotype V between
the first study (1988–1997) [16] and the second study
(1998–2001) (p = 0.007 when serotype V was compared
with all other serotypes) [17]. Serotype V has remained
Table 3 Patients with more than one invasive isolates of group B streptococci
Patient no. Age (months) Serotype Manifestation Time between infections (months) Underlying condition
1 81 Ib Septic arthritis 9 Prosthetic hip, malignancy
81 Ib Septic arthritis
2 79 V Septic arthritis 3 Prosthetic hip
79 V Septic arthritis
3 77 III Urosepsis 2 Chronic urinary catheter malignancy, dementia
77 Ib Urosepsis
4 73 V Sepsis, unknown focus 4 Heart valve operation
73 V Mediastinitis
5 67 Ia Spondylitis 2 Spinal stenosis
68 Ia Spondylitis
6 62 II Erysipelas 10 Progressive multiple sclerosis, urostomy
63 II Erysipelas
7 60 V Septic arthritis 8 Ischaemic Heart Disease
60 V Endocarditis
8 61 V Erysipelas 8 Malignancy. Died after the skeptical infection
62 IV Sepsis, unknown focus
9 46 V Urosepsis 23 Chronic urinary catheter
48 II Urosepsis
10 33 V Septic arthritis 22 Chronic renal failure, urostomy
34 II Septic arthritis
11 82 V Erysipelas 10 Malignancy
83 V Erysipelas 25
85 III Erysipelas
Table 2 Serotype distribution of invasive group B streptococci related to clinical manifestation in adults
Serotype
Manifestation Ia Ib II III IV V VIII IX Total (%)
Sepsis, unknown focus 11 13 9 20 5 32 0 2 92 (29)
Erysipelas 12 13 7 9 1 30 2 1 75 (24)
Septic arthritis* 3 6 3 8 2 29 0 1 52 (16)
Urosepsis 3 6 4 12 2 12 0 2 41 (13)
Pneumonia 1 2 3 4 2 9 1 0 22 (7)
Endocarditis 2 3 1 5 1 7 0 1 20 (6)
Meningitis 1 0 0 3 0 0 0 0 4 (1)
Othera 1 2 2 1 1 4 0 0 11 (3)
Missing clinical data 0 0 0 0 0 1 0 0 1 (0,3)
Total (%) 34 (11) 45 (14) 29 (9) 62 (20) 14 (4) 124 (39) 3 (1) 7 (2) 318
*p = 0.008 and p = 0.03 when the proportion of arthritis was caused by serotype V and III respectively was compared with the proportion of arthritis for all
other serotypes
aChorioamnionitis, Mediastinitis, Periotinitis, Cholecystitis, Vulvitis
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on approximately the same high level among adults in
the present study. Serotype III has been the most
prevalent serotype isolated from neonates and infants
in all three studies from south-west Sweden since 1988
[16, 17, present study]. Serotypes Ia, Ib, II, III and IV
have shown some fluctuations between the studies, but
all differences were non-significant and showed no ob-
vious trends over time. There were a few cases of sero-
type VII-IX, both in children and adults, which have
not previously been seen in this area. Serotype VI has
remained absent.
Discussion
The differences in serotype distribution between neo-
nates/infants and adults must be considered in future
GBS vaccines. Pregnant women are the obvious target
for GBS vaccination in order to protect neonates from
early onset disease through passively transferred anti-
bodies, so (at least currently) the most important in a
vaccine must be type III followed by serotype Ia while
serotype V seems to be of little importance. A GBS vac-
cine for elderly or patients with severe underlying dis-
eases, in which serotype V infections are the most
common, is probably unrealistic. There has been little
change in serotype distribution among neonates and in-
fants over the last 30 years, even after the rise of sero-
type V among adults [5]. Serotype V was first reported in
1985 and soon became the most common serotype
among adults in many parts of the world [17–19].
The present study showed that five serotypes, Ia, Ib, II,
III and V, accounted for 94 % (neonates and infants) and
93 % (adults) of cases with invasive GBS infections. This is
consistent with studies from other countries [2, 5, 20, 21].
Serotype III is still the most common serotype among ne-
onates and infants, especially for LO disease [5, 11, 13, 19,
20, 22]. Other studies have shown a dominance of sero-
type Ia for EO disease [19, 23, 24]. A possible reason for
this differences between different parts of the world could
be that GBS has similarities with pneumococci. It is well
known that serotypes of pneumococci change region-
ally and over time [25, 26]. This was seen already in the
prevaccination era. One example is the increase in
pneumococcal serogroup 1 in Northern Europe [27–29].
A reason for this could be that pneumococci have differ-
ent clones with different virulence within the same sero-
type. This has been suggested to be the case in increase of
pneumococcal serogroup 1. Possibly this may be true also
for GBS.
It has previously been suggested that a trivalent vac-
cine has the potential to further reduce the burden of
GBS disease and especially LO cases [30]. Regarding our
findings a trivalent vaccine (CRM197-conjugated capsu-
lar polysaccharides of GBS serotypes Ia, Ib and III),
could have had an impact on 80 % (24/30) of the LO
cases and 75 % (69/92) of all infants and neonates in our
population during the study period. Several studies have
shown serotype replacement among pneumococci when
pneumococcal conjugate vaccines have been used in
large scale for some years [31–33]. Only future can tell if
this will occur also among GBS if such vaccines are used
extensively.
Such a vaccine would have little impact on GBS diseases
in adults, e.g. those with severe underlying diseases.
Among adults three serotypes, Ia, III and V account for
70 % of cases with invasive GBS infections. Other stud-
ies have reported similar findings (64–71.8 %) but with
variation in which of the three is the most prevalent
[2, 18, 20, 22, 34, 35].
Some studies have reported an increase in serotype IV
among invasive GBS isolates [36, 37]. We did not see
Table 4 Serotype distribution of invasive group B streptococci isolates in the present study compared with two previous studies in
the same region
Neonates and infants Adults
Berg et al. [15] Persson et al. [16] Present study Berg et al. [15] Persson et al. [16] Present study
Serotype No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Ia 14 (18) 5 (10) 17 (18) 4 (6) 10 (9) 34 (11)
Ib 2 (3) 2 (4) 5 (6) 15 (23) 10 (9) 45 (14)
II 4 (5) 1 (2) 5 (6) 10 (15) 7 (6) 29 (9)
III 48 (62) 30 (60) 44 (48) 19 (29) 28 (25) 62 (20)
IV 2 (3) 1 (2) 2 (2) 1 (2) 8 (7) 14 (4)
V 7 (9) 11 (22) 15 (16) 14 (21) 47 (42) 124 (39)
VII 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1)
VIII 0 (0) 0 (0) 3 (1) 0 (0) 0 (0) 1 (1)
IX 0 (0) 0 (0) 7 (2) 0 (0) 0 (0) 2 (2)
Non-typeable 1 (1) 0 (0) 0 (0) 3 (5) 1 (1) 0 (0)
The present study covers a longer time span than the two previous, which explains the increased number of cases
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any rise of serotype IV in the present study in compari-
son with the two previous studies done in the same re-
gion [16, 17]. Other studies show like ours that these
serotypes are nonexistent or very uncommon [22, 23].
There were few relations between serotype and clinical
manifestations but the study showed that serotypes V and
III were found more often isolated from synovial fluid in
adults but others have found it to be serotype II [38].
Conclusions
In conclusion, this study has shown that there have not
been any significant changes of the serotype distribution
of invasive GBS infections in this Swedish population
since the emergence of serotype V in the late 1990s but
a few cases of serotypes VII-IX, which are not being tar-
geted with a vaccine, have emerged in the area. It is
therefore important to have an ongoing surveillance of
GBS even though a trivalent vaccine would probably
lead to much less disease among neonates and infants.
Abbreviations
GBS: Group B Streptococci; CPS: Capsular polysaccharide; IAP: Intra partum
antimicrobial prophylaxis; EO: Early onset; LO: Late onset; VLO: Very late
onset; IUFD: Intrauterine fetal death.
Competing interests
No financial or non-financial competing interests exist.
Authors’ contributions
MJG participated in acquisition, analysis and interpretation of data, drafted
the manuscript and performed the statistical analyses. EH was main
responsible and first author of the second of the GBS serotype studies in
western Sweden and participated in acquisition of data, the design of the
study and revision of the manuscript. SB was main responsible and first
author of the first of the GBS serotype studies in western Sweden and
participated in the planning of the present study and commented on the
final version. EB participated in acquisition of data. AE participated in
acquisition of data and revision of the manuscript. SK performed the
serotyping. BT conceived of the study and participated in its design and
coordination and helped to draft the manuscript. All authors approved the
final manuscript.
Acknowledgements
The staff at the Microbiological Laboratories in Gothenburg, Borås, Skövde and
Trollhättan for collecting the strains and sending them frozen to us. Financial
support was obtained from the Health and Medical Care Committee of the
Region Västra Götaland.
Author details
1Division of Neonatology, Department of Paediatrics, Institute of Clinical
Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg,
Sweden. 2Department of Pediatrics, Queen Silvia Childrens’ Hospital,
Sahlgrenska University Hospital, Gothenburg, Sweden. 3Department of
Infectious Diseases, Skaraborg Hospital, Skövde, Sweden. 4Department of
Bacteriology, Sahlgrenska University Hospital, Gothenburg, Sweden.
5Department of Pediatrics, Neonatology, Sahlgrenska University Hospital,
41685 Gothenburg, Sweden.
Received: 7 July 2015 Accepted: 5 November 2015
References
1. Schrag SJ, Zywicki S, Farley MM, Reingold AL, Harrison LH, Lefkowitz LB, et
al. Group B streptococcal disease in the era of intrapartum antibiotic
prophylaxis. N Engl J Med. 2000;342:15–20.
2. Skoff TH, Farley MM, Petit S, Craig AS, Schaffner W, Gershman K, et al.
Increasing burden of invasive group B streptococcal disease in nonpregnant
adults, 1990–2007. Clin Infect Dis. 2009;49:85–92.
3. Sendi P, Johansson L, Norrby-Teglund A. Invasive group B streptococcal
disease in non-pregnant adults. Infection. 2008;36:100–11.
4. Slotved H-C, Kong F, Lambertsen L, Sauer S, Gilbert GL. Serotype IX, a
proposed new Streptococcus agalactiea serotype. J Clin Microbiol.
2007;45:2929–36.
5. Edmond KM, Kortsalioudaki C, Scott S, Schrag SJ, Zaidi AK, Cousens S, et al.
Group B streptococcal disease in infants aged younger than 3 months:
systematic review and meta-analysis. Lancet. 2012;379:547–56.
6. Lin FY, Philips JB, Azimi PH, Weisman LE, Clark P, Rhoads GG, et al. Level of
maternal antibody required to protect neonates against early-onset disease
caused by group B streptococcus type Ia: a multicenter seroepidemiology
study. J Infect Dis. 2001;184:1022–8.
7. Bergseng H, Rygg M, Bevanger L, Bergh K. Invasive group B streptococcus
(GBS) disease in Norway 1996–2006. Eur J Clin Microbiol Infect Dis.
2008;27:1193–9.
8. Jacobsson B, Håkansson S. Infpreg: Grupp B streptokocker (in Swedish).
Available online at: http://www.medscinet.se/infpreg/specinfo/specinfo.asp
(accessed 16 April 2015).
9. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group
B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep.
2002;51:1–22.
10. Lukacs SL, Schoendorf KC, Schuchat A. Trends in sepsis-related neonatal
mortality in the United States, 1985–1998. Pediatr Infect Dis J. 2004;23:599–603.
11. Moore MR, Schrag SJ, Schuchat A. Effects of intrapartum antimicrobial
prohylaxis for prevention of group-B-streptococcal disease on the incidence
and ecology of early-onset neonatal sepsis. Lancet Infect Dis. 2003;3:201–13.
12. Poyart C, Reglier-Poupet H, Tazi A, Billoët A, Dmytruk N, Bidet P, et al.
Invasive group B streptococcal infections in infants. France Emerg Infect Dis.
2008;14:1647–9.
13. Lin FY, Brenner RA, Johnson YR, Azimi PH, Phillips JB 3rd, Regan JA, et al.
The effectiveness of risk-based intrapartum chemoprophylaxis for the
prevention of early-onset neonatal group B streptococcal disease. Am J
Obstet Gynecol. 2001;184:1204–10.
14. Nuticelli A, Rinaudo CD, Maione D. Group B Streptococcus vaccine: state of
the art. Ther Adv Vaccines. 2015;3:76–90.
15. Slotved HC, Elliot J, Thompson T, Konradsen HB . Latex assay for serotyping
of group B Streptococcus isolates. J Clin Microbiol. 2003;41:4445–7.
16. Berg S, Trollfors B, Lagergard T, Zackrisson G, Claesson BA. Serotypes and
clinical manifestations of group B streptococcal infections in western
Sweden. Clin Microbiol Infect. 2000;6:9–13.
17. Persson E, Berg S, Trollfors B, Larsson P, Ek E, Backhaus E, et al. Serotypes
and clinical manifestations of invasive group B streptococcal infections in
western Sweden 1998–2001. Clin Microbiol Infect. 2004;10:791–6.
18. Teatero S, McGeer A, Low DE, Li A, Demczuk W, Martin I, et al.
Characterization of invasive group B streptococcus strains from the greater
Toronto area, Canada. J Clin Microbiol. 2014;52:1441–7.
19. Jelinkova J, Motlova J. Worldwide distribution of two new serotypes of
group B streptococci: type IV and provisional type V. J Clin Microbiol.
1985;21:361–2.
20. Oladottir GL, Erlendsdottir H, Palsson G, Björnsdottir ES, Kristinsson KG,
Haraldsson Á. Increasing incidence of late-onset neonatal invasive group B
streptococcal infections in Iceland. Pediatr Infec Dis J. 2011;30:661–3.
21. Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults.
Clin Infect Dis. 2005;41:839–47.
22. Bellais S, Six A, Fouet A, Longo M, Dmytruk N, Glaser P, et al. Capsular
switching in group B streptococcus CC17 hypervirulent clone: a future
challenge for polysachharide vaccine development. J Infect Dis.
2012;206:1745–52.
23. Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S, et al.
Epidemiology of invasive group B streptococcal disease in the United States
1999–2005. JAMA. 2008;299:2056–65.
24. Morozumi M, Wajima T, Kuwata Y, Chiba N, Sunaoshi K, Sugita K, et al.
Associations between capsular serotype, multilocus sequence type, and
macrolide resistance in Streptoccus agalactiae isolates from Japanese infants
with invasive infections. Epidemiol Infect. 2014;142:812–9.
25. Browall S, Norman M, Tångrot J, Galanis I, Sjöström K, Dagerhamn JW, et al.
Intraclonal variations among Streptococcus pneumoniae isolates influence
the likelihood of invasive disease in children. J Infect Dis. 2014;209:377–88.
Gudjónsdóttir et al. BMC Infectious Diseases  (2015) 15:507 Page 6 of 7
26. Hsieh YC, Lin TL, Chang KY, Huang YC, Chen CJ, Lin TY, et al. Expansion and
evolution of Streptococcus pneumoniae serotype 19A ST320 clone as to its
ancestral clone, Taiwan19F-14 (ST236). J Infect Dis. 2013;208:203–10.
27. Berg S, Trollfors B, Persson E, Backhaus E, Larsson P, Ek E, et al. Serotypes of
Streptococcus pneumoniae isolated from blood and cerebrospinal fluid
related to vaccine serotypes and to clinical characteristics. Scand J Infect
Dis. 2006;38:427–32.
28. Konradsen HB, Kaltoft MS. Invasive pneumococcal infections in Denmark
from 1995 to 1999: epidemiology, serotypes, and resistance. Clin Diagn Lab
Immunol. 2002;9:358–65.
29. Pedersen MK, Hoiby EA, Froholm LO, Hasseltvedt V, Lermark G, Caugant DA.
Systemic pneumococcal disease in Norway 1995–2001: capsular serotypes
and antimicrobial resistance. Epidemiol Infect. 2004;132:167–75.
30. Oster G, Edelsberg J, Hennegan K, Lewin C, Narasimhan V, Slobod K, et al.
Prevention of group B streptococcal disease in the first 3 months of life:
would routine maternal immunization during pregnancy be cost-effective?
Vaccine. 2014;32:4778–85.
31. Gladstone RA, Jefferies JM, Tocheva AS, Beard KR, Garley D, Chong WW, et
al. Five winters of pneumococcal serotype replacement in UK carriage
following PCV introduction. Vaccine. 2015;33:2015–21.
32. Henriques Normark B, Kalin M, Ortqvist A, Akerlund T, Liljequist BO, Hedlund
J, et al. Dynamics of penicillinsusceptible clones in invasive pneumococcal
disease. J Infect Dis. 2001;184:861–9.
33. Phongsamart W, Srifeungfung S, Chatsuwan T, Nunthapisud P,
Treerauthaweeraphong V, Rungnobhakhun P, et al. Changing trends in
serotype distribution and antimicrobial susceptibility of Streptococcus
pneumoniae causing invasive diseases in Central Thailand, 2009–2012. Hum
Vaccin Immunother. 2014;10:866–73.
34. Tazi A, Morand PC, Reglier-Poupet H, Dmytruk N, Billoët A, Antona D, et al.
Invasive group B streptococcal infections in adults, France (2007–2010). Clin
Microbiol Infect. 2011;17:1587–9.
35. Lambertsen L, Ekelund K, Skovsted IC, Liboriussen A, Slotved HC.
Characterisation of invasive group B streptococci from adults in Denmark
1999 to 2004. Eur J Clin Microbiol Infect Dis. 2010;29:1071–7.
36. Meehan M, Cunney R, Cafferkey M. Molecular epidemiology of group B
streptococci in Ireland reveals a diverse population with evidence of
capsular switching. Eur J Clin Microbiol Infect Dis. 2014;33:1155–62.
37. Shet A, Ferrieri P. Neonatal & maternal group B streptococcal infections: a
comprehensive review. Indian J Med Res. 2004;120:141–50.
38. Martins ER, Melo-Cristino J, Ramirez M, the Portugese Group for the Study
of Streptococcal Infections. Dominance of serotype Ia among group B
streptococci causing invasive infections in nonpregnant adults in Portugal. J
Clin Microbiol. 2012;50:1219–27.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gudjónsdóttir et al. BMC Infectious Diseases  (2015) 15:507 Page 7 of 7
